This company listing is no longer active
Indivior Management
Management criteria checks 2/4
Indivior's CEO is Mark Crossley, appointed in Jun 2020, he has a tenure of 6.33 years. His total yearly compensation is $10.69M , comprised of 7.5% salary and 92.5% bonuses, including company stock and options. He directly owns 0.065% of the company’s shares, worth $1.97M. The average tenure of the management team and the board of directors is 3.2 years and 3.1 years respectively.
Key information
Mark Crossley
Chief executive officer
US$10.7m
Total compensation
| CEO salary percentage | 7.54% |
| CEO tenure | 3yrs |
| CEO ownership | 0.07% |
| Management average tenure | 3.2yrs |
| Board average tenure | 3.1yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2023 | n/a | n/a | -US$50m |
| Dec 31 2022 | US$11m | US$806k | -US$53m |
| Sep 30 2022 | n/a | n/a | US$166m |
| Jun 30 2022 | n/a | n/a | US$152m |
| Mar 31 2022 | n/a | n/a | US$166m |
| Dec 31 2021 | US$5m | US$775k | US$205m |
| Sep 30 2021 | n/a | n/a | US$156m |
| Jun 30 2021 | n/a | n/a | US$139m |
| Mar 31 2021 | n/a | n/a | US$95m |
| Dec 31 2020 | US$761k | US$675k | -US$148m |
| Sep 30 2020 | n/a | n/a | -US$190m |
| Jun 30 2020 | n/a | n/a | -US$152m |
| Mar 31 2020 | n/a | n/a | -US$95m |
| Dec 31 2019 | US$1m | US$528k | US$134m |
| Sep 30 2019 | n/a | n/a | US$213m |
| Jun 30 2019 | n/a | n/a | US$254m |
| Mar 31 2019 | n/a | n/a | US$248m |
| Dec 31 2018 | US$551k | US$494k | US$275m |
| Sep 30 2018 | n/a | n/a | US$106m |
| Jun 30 2018 | n/a | n/a | US$67m |
| Mar 31 2018 | n/a | n/a | US$71m |
| Dec 31 2017 | US$2m | US$413k | US$58m |
Compensation vs Market: Mark's total compensation ($USD10.69M) is above average for companies of similar size in the US market ($USD6.77M).
Compensation vs Earnings: Mark's compensation has increased whilst the company is unprofitable.
CEO
Mark Crossley
Mr. Mark Crossley has been Chief Executive Officer of Indivior PLC since June 29, 2020 and served as its Chief Financial and Operations Officer since July 29, 2019 until June 29, 2020. He has a wealth of f...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 3yrs | US$10.69m | 0.065% $ 2.0m | |
| CFO & Executive Director | 3yrs | US$2.32m | 0.047% $ 1.4m | |
| Chief Scientific Officer | no data | no data | 0.067% $ 2.0m | |
| Vice President of Investor Relations | no data | no data | no data | |
| Chief Integrity & Compliance Officer | 4.7yrs | no data | 0.088% $ 2.7m | |
| Chief Legal Officer | 1.5yrs | no data | no data | |
| Chief Human Resources Officer | 8.7yrs | no data | 0.044% $ 1.3m | |
| Chief Commercial Officer | no data | no data | 0.064% $ 1.9m | |
| Chief Manufacturing & Supply Officer | 3.3yrs | no data | 0.020% $ 605.3k | |
| Chief Global Impact Officer | 1.1yrs | no data | no data | |
| Senior VP of US Treatment Access | no data | no data | 0.063% $ 1.9m | |
| Company Secretary | 8yrs | no data | 0.022% $ 676.4k |
Experienced Management: INVV.Y's management team is considered experienced (3.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 6.3yrs | US$10.69m | 0.065% $ 2.0m | |
| CFO & Executive Director | 2.6yrs | US$2.32m | 0.047% $ 1.4m | |
| Independent Chairman | 3.6yrs | US$332.44k | 0.011% $ 345.9k | |
| Senior Independent Director | 8.6yrs | US$153.50k | 0.016% $ 481.6k | |
| Independent Non-Executive Director | 2.3yrs | US$102.75k | no data | |
| Independent Non-Executive Director | 3.8yrs | US$102.75k | 0.0078% $ 235.7k | |
| Independent Non-Executive Director | 1yr | US$58.30k | no data | |
| Independent Non-Executive Director | 2.3yrs | US$110.10k | 0.0070% $ 211.3k | |
| Non-Executive Director | 2.3yrs | US$101.60k | 0.000050% $ 1.5k | |
| Independent Non-Executive Director | 8.6yrs | US$90.67k | 0.0037% $ 112.9k | |
| Independent Non-Executive Director | 8.6yrs | US$110.10k | 0.0011% $ 32.8k | |
| Independent Non-Executive Director | 2.3yrs | US$90.67k | no data |
Experienced Board: INVV.Y's board of directors are considered experienced (3.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/06/13 20:32 |
| End of Day Share Price | 2023/06/09 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Indivior Pharmaceuticals, Inc. is covered by 12 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Graham Glyn Parry | BofA Global Research |
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |
| Brandon Folkes | H.C. Wainwright & Co. |